Systematic review on the use of biosimilars of trastuzumab in her2+ breast cancer

HIGHLIGHTS

  • who: Eleni Triantafyllidi and John K. Triantafillidis from the Hellenic Society of Gastrointestinal Oncology, Iera Odos Street, Haidari, Athens, Greece have published the article: Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer, in the Journal: Biomedicines 2022, 10, 2045. of 25/Nov/2010
  • what: In this systematic review, the authors report the clinical data regarding the treatment of patients with HER2+ BC with the use of biosimilars-both those available and those under evaluation-to trastuzumab monoclonal_antibodies. Of these, 221 were excluded for the following reasons: (i) not relevant to . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?